CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP ...
A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using ...
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
In 2020, Jennifer Doudna, Ph.D., received the Nobel Prize in Chemistry, CRISPR-Cas9, a method for genome editing. Often referred to as “molecular scissors,” CRISPR cuts DNA at specific locations that ...
The practice of genetic modification is as old as humanity. For thousands of years, humans have bred crops, livestock and even pets that possess desirable traits. This selective process, which alters ...
Since the landmark discovery that a bacterial defense mechanism could be repurposed into programmable “molecular scissors,” CRISPR-Cas9 gene-editing technology has undergone a major evolution. Over ...
Researchers have identified critical spots on the genome where gene editing could cause an unwanted response, and they provide recommendations for safer approaches. CRISPR/Cas9 is a commonly used, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results